Dynavax Technologies reported $999.34M in Assets for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Adma Biologics ADMA:US USD 300.56M 3.63M
Agenus AGEN:US USD 429.02M 27.15M
Amgen AMGN:US USD 63.7B 4.41B
Astrazeneca AZN:US USD 94.18B 2.39B
AstraZeneca AZN:LN USD 94.18B 2.39B
Biogen BIIB:US USD 24.85B 227.2M
Biomarin Pharmaceutical BMRN:US USD 6.26B 118.2M
Bristol Myers Squibb BMY:US USD 98.2B 2.16B
Chimerix CMRX:US USD 293.88M 240.32M
Dynavax Technologies DVAX:US USD 999.34M 23.66M
Gilead Sciences GILD:US USD 62.56B 313M
Glaxosmithkline GSK:US GBP 60.31B 28.73B
Idera Pharmaceuticals IDRA:US USD 103.68M 77.38M
Merk MRK:US USD 107.08B 14M
Minerva Neurosciences NERV:US USD 59.76M 5.2M
Nektar Therapeutics NKTR:US USD 781.01M 80.98M
Neurocrine Biosciences NBIX:US USD 2.14B 137.7M
Novartis NOVN:VX USD 118.46B 4.45B
Pfizer PFE:US USD 195.35B 60M
Regeneron Pharmaceuticals REGN:US USD 27.68B 472M
Roche Holding ROG:VX 86.74B 5.58B
Sarepta Therapeutics SRPT:US USD 3.16B 159.3M
Tg Therapeutics TGTX:US USD 217.89M 33.78M
Vertex Pharmaceuticals VRTX:US USD 16.71B 1.12B